Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies
Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies, and materials for their technological significance that are available for sale or license. The R&D 100 Awards, celebrating the program's 60th Anniversary this year, has long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology. This 2022 R&D 100 winner is listed below, along with its respective category.
Category: Analytical/Test
Developers: Sandia National Laboratories Sandia National Laboratories
United States
Product Description:Using a library of variable antibody fragments (nanobodies) derived from heavy chain antibodies, we identified next-generation anti-SARS-CoV-2 neutralizing antibodies. These nanobody-based SARS-CoV-2 antibodies provide easier manufacturability, increased versatility, smaller size, and the ability to bind to more than one target site to increases potency and resistance to viral escape mutants.
Developers: Sandia National Laboratories Sandia National Laboratories
United States
Product Description:Using a library of variable antibody fragments (nanobodies) derived from heavy chain antibodies, we identified next-generation anti-SARS-CoV-2 neutralizing antibodies. These nanobody-based SARS-CoV-2 antibodies provide easier manufacturability, increased versatility, smaller size, and the ability to bind to more than one target site to increases potency and resistance to viral escape mutants.
Anti-SARS-CoV2